Rachel F. Tyndale, Ph.D. - Publications

Affiliations: 
Departments of Pharmacology and Toxicology and Psychiatry CAMH/University of Toronto 
Area:
Addiction, Drug Metabolism
Website:
http://www.pharmtox.utoronto.ca/faculty/directory/tyndale.htm

263 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any innacuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2018 Tyndale RF, Sellers EM. Opioids: The Painful Public Health Reality. Clinical Pharmacology and Therapeutics. 103: 924-935. PMID 29878319 DOI: 10.1002/cpt.1074  0.48
2017 McMillan DM, Miksys S, Tyndale RF. Rat brain CYP2D activity alters in vivo central oxycodone metabolism, levels and resulting analgesia. Addiction Biology. PMID 29266563 DOI: 10.1111/adb.12590  0.52
2017 Chenoweth MJ, Ware JJ, Zhu AZX, Cole CB, Cox LS, Nollen N, Ahluwalia JS, Benowitz NL, Schnoll RA, Hawk LW, Cinciripini PM, George TP, Lerman C, Knight J, Tyndale RF, et al. Genome-wide association study of a nicotine metabolism biomarker in African American smokers: impact of chromosome 19 genetic influences. Addiction (Abingdon, England). PMID 28921760 DOI: 10.1111/add.14032  0.68
2017 Miksys S, Wadji FB, Tolledo EC, Remington G, Nobrega JN, Tyndale RF. Rat brain CYP2D enzymatic metabolism alters acute and chronic haloperidol side-effects by different mechanisms. Progress in Neuro-Psychopharmacology & Biological Psychiatry. PMID 28454738 DOI: 10.1016/j.pnpbp.2017.04.030  0.52
2016 Ross KC, Gubner NR, Tyndale RF, Hawk LW, Lerman C, George TP, Cinciripini P, Schnoll RA, Benowitz NL. Racial differences in the relationship between rate of nicotine metabolism and nicotine intake from cigarette smoking. Pharmacology, Biochemistry, and Behavior. PMID 27180107 DOI: 10.1016/j.pbb.2016.05.002  1
2016 Avey JP, Hiratsuka VY, Beans JA, Trinidad SB, Tyndale RF, Robinson RF. Perceptions of pharmacogenetic research to guide tobacco cessation by patients, providers and leaders in a tribal healthcare setting. Pharmacogenomics. PMID 26871371 DOI: 10.2217/pgs.15.177  1
2016 Ware JJ, Chen X, Vink J, Loukola A, Minica C, Pool R, Milaneschi Y, Mangino M, Menni C, Chen J, Peterson RE, Auro K, Lyytikäinen LP, Wedenoja J, Stiby AI, ... ... Tyndale RF, et al. Genome-Wide Meta-Analysis of Cotinine Levels in Cigarette Smokers Identifies Locus at 4q13.2. Scientific Reports. 6: 20092. PMID 26833182 DOI: 10.1038/srep20092  0.68
2015 Wassenaar CA, Zhou Q, Tyndale RF. CYP2A6 genotyping methods and strategies using real-time and endpoint PCR platforms. Pharmacogenomics. PMID 26670214 DOI: 10.2217/pgs.15.156  1
2015 Webb A, Papp AC, Curtis A, Newman LC, Pietrzak M, Seweryn M, Handelman SK, Rempala GA, Wang D, Graziosa E, Tyndale RF, Lerman C, Kelsoe JR, Mash DC, Sadee W. RNA sequencing of transcriptomes in human brain regions: protein-coding and non-coding RNAs, isoforms and alleles. Bmc Genomics. 16: 990. PMID 26597164 DOI: 10.1186/s12864-015-2207-8  1
2015 Loukola A, Buchwald J, Gupta R, Palviainen T, Hällfors J, Tikkanen E, Korhonen T, Ollikainen M, Sarin AP, Ripatti S, Lehtimäki T, Raitakari O, Salomaa V, Rose RJ, Tyndale RF, et al. A Genome-Wide Association Study of a Biomarker of Nicotine Metabolism. Plos Genetics. 11: e1005498. PMID 26407342 DOI: 10.1371/journal.pgen.1005498  1
2015 Alsharari SD, King JR, Nordman JC, Muldoon PP, Jackson A, Zhu AZ, Tyndale RF, Kabbani N, Damaj MI. Effects of Menthol on Nicotine Pharmacokinetic, Pharmacology and Dependence in Mice. Plos One. 10: e0137070. PMID 26355604 DOI: 10.1371/journal.pone.0137070  1
2015 Dubroff JG, Doot RK, Falcone M, Schnoll RA, Ray R, Tyndale RF, Brody AL, Hou C, Schmitz A, Lerman C. Decreased Nicotinic Receptor Availability in Smokers with Slow Rates of Nicotine Metabolism. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 56: 1724-9. PMID 26272810 DOI: 10.2967/jnumed.115.155002  1
2015 Kaufmann A, Hitsman B, Goelz PM, Veluz-Wilkins A, Blazekovic S, Powers L, Leone FT, Gariti P, Tyndale RF, Schnoll RA. Rate of Nicotine Metabolism and Smoking Cessation Outcomes in a Community-based Sample of Treatment-Seeking Smokers. Addictive Behaviors. 51: 93-9. PMID 26240944 DOI: 10.1016/j.addbeh.2015.07.019  1
2015 Bergen AW, Michel M, Nishita D, Krasnow R, Javitz HS, Conneely KN, Lessov-Schlaggar CN, Hops H, Zhu AZ, Baurley JW, McClure JB, Hall SM, Baker TB, Conti DV, Benowitz NL, ... ... Tyndale RF, et al. Drug Metabolizing Enzyme and Transporter Gene Variation, Nicotine Metabolism, Prospective Abstinence, and Cigarette Consumption. Plos One. 10: e0126113. PMID 26132489 DOI: 10.1371/journal.pone.0126113  1
2015 Boileau I, Tyndale RF, Williams B, Mansouri E, Westwood DJ, Foll BL, Rusjan PM, Mizrahi R, De Luca V, Zhou Q, Wilson AA, Houle S, Kish SJ, Tong J. The fatty acid amide hydrolase C385A variant affects brain binding of the positron emission tomography tracer [(11)C]CURB. Journal of Cerebral Blood Flow and Metabolism : Official Journal of the International Society of Cerebral Blood Flow and Metabolism. PMID 26036940 DOI: 10.1038/jcbfm.2015.119  1
2015 Tanner JA, Novalen M, Jatlow P, Huestis MA, Murphy SE, Kaprio J, Kankaanpää A, Galanti L, Stefan C, George TP, Benowitz NL, Lerman C, Tyndale RF. Nicotine Metabolite Ratio (3-Hydroxycotinine/Cotinine) in Plasma and Urine by Different Analytical Methods and Laboratories: Implications for Clinical Implementation. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. PMID 26014804 DOI: 10.1158/1055-9965.EPI-14-1381  1
2015 Tyndale RF, Zhu AZ, George TP, Cinciripini P, Hawk LW, Schnoll RA, Swan GE, Benowitz NL, Heitjan DF, Lerman C. Lack of Associations of CHRNA5-A3-B4 Genetic Variants with Smoking Cessation Treatment Outcomes in Caucasian Smokers despite Associations with Baseline Smoking. Plos One. 10: e0128109. PMID 26010901 DOI: 10.1371/journal.pone.0128109  1
2015 Foti RS, Tyndale RF, Garcia KL, Sweet DH, Nagar S, Sharan S, Rock DA. "Target-Site" Drug Metabolism and Transport. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 43: 1156-68. PMID 25986849 DOI: 10.1124/dmd.115.064576  1
2015 Zhu AZ, Cox LS, Ahluwalia JS, Renner CC, Hatsukami DK, Benowitz NL, Tyndale RF. Genetic and phenotypic variation in UGT2B17, a testosterone-metabolizing enzyme, is associated with BMI in males. Pharmacogenetics and Genomics. 25: 263-9. PMID 25794161 DOI: 10.1097/FPC.0000000000000135  1
2015 Hamilton DA, Mahoney MC, Novalen M, Chenoweth MJ, Heitjan DF, Lerman C, Tyndale RF, Hawk LW. Test-Retest Reliability and Stability of the Nicotine Metabolite Ratio Among Treatment-Seeking Smokers. Nicotine & Tobacco Research : Official Journal of the Society For Research On Nicotine and Tobacco. PMID 25732567 DOI: 10.1093/ntr/ntv031  1
2015 Tanner JA, Chenoweth MJ, Tyndale RF. Pharmacogenetics of nicotine and associated smoking behaviors. Current Topics in Behavioral Neurosciences. 23: 37-86. PMID 25655887 DOI: 10.1007/978-3-319-13665-3_3  1
2015 Garcia KL, Coen K, Miksys S, Lê AD, Tyndale RF. Effect of Brain CYP2B Inhibition on Brain Nicotine Levels and Nicotine Self-Administration. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 40: 1910-8. PMID 25652250 DOI: 10.1038/npp.2015.40  1
2015 McMillan DM, Tyndale RF. Nicotine Increases Codeine Analgesia Through the Induction of Brain CYP2D and Central Activation of Codeine to Morphine. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 40: 1804-12. PMID 25630571 DOI: 10.1038/npp.2015.32  1
2015 Lerman C, Schnoll RA, Hawk LW, Cinciripini P, George TP, Wileyto EP, Swan GE, Benowitz NL, Heitjan DF, Tyndale RF. Use of the nicotine metabolite ratio as a genetically informed biomarker of response to nicotine patch or varenicline for smoking cessation: a randomised, double-blind placebo-controlled trial. The Lancet. Respiratory Medicine. 3: 131-8. PMID 25588294 DOI: 10.1016/S2213-2600(14)70294-2  1
2015 Bandiera FC, Ross KC, Taghavi S, Delucchi K, Tyndale RF, Benowitz NL. Nicotine Dependence, Nicotine Metabolism, and the Extent of Compensation in Response to Reduced Nicotine Content Cigarettes. Nicotine & Tobacco Research : Official Journal of the Society For Research On Nicotine and Tobacco. PMID 25555385 DOI: 10.1093/ntr/ntu337  1
2015 Wassenaar CA, Conti DV, Das S, Chen P, Cook EH, Ratain MJ, Benowitz NL, Tyndale RF. UGT1A and UGT2B genetic variation alters nicotine and nitrosamine glucuronidation in european and african american smokers. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 24: 94-104. PMID 25277794 DOI: 10.1158/1055-9965.EPI-14-0804  1
2014 Tani N, Juvonen RO, Raunio H, Fashe M, Leppänen J, Zhao B, Tyndale RF, Rahnasto-Rilla M. Rational design of novel CYP2A6 inhibitors. Bioorganic & Medicinal Chemistry. 22: 6655-64. PMID 25458499 DOI: 10.1016/j.bmc.2014.10.001  1
2014 Garcia KL, Lê AD, Tyndale RF. Effect of food training and training dose on nicotine self-administration in rats. Behavioural Brain Research. 274: 10-8. PMID 25101539 DOI: 10.1016/j.bbr.2014.07.043  1
2014 Chenoweth MJ, Novalen M, Hawk LW, Schnoll RA, George TP, Cinciripini PM, Lerman C, Tyndale RF. Known and novel sources of variability in the nicotine metabolite ratio in a large sample of treatment-seeking smokers. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 23: 1773-82. PMID 25012994 DOI: 10.1158/1055-9965.EPI-14-0427  1
2014 Craig EL, Zhao B, Cui JZ, Novalen M, Miksys S, Tyndale RF. Nicotine pharmacokinetics in rats is altered as a function of age, impacting the interpretation of animal model data. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 42: 1447-55. PMID 24980255 DOI: 10.1124/dmd.114.058719  1
2014 Bagdas D, Muldoon PP, Zhu AZ, Tyndale RF, Damaj MI. Effects of methoxsalen, a CYP2A5/6 inhibitor, on nicotine dependence behaviors in mice. Neuropharmacology. 85: 67-72. PMID 24859605 DOI: 10.1016/j.neuropharm.2014.05.006  1
2014 Khokhar JY, Tyndale RF. Intracerebroventricularly and systemically delivered inhibitor of brain CYP2B (C8-Xanthate), even following chlorpyrifos exposure, reduces chlorpyrifos activation and toxicity in male rats. Toxicological Sciences : An Official Journal of the Society of Toxicology. 140: 49-60. PMID 24798379 DOI: 10.1093/toxsci/kfu075  1
2014 Zhu AZ, Zhou Q, Cox LS, David SP, Ahluwalia JS, Benowitz NL, Tyndale RF. Association of CHRNA5-A3-B4 SNP rs2036527 with smoking cessation therapy response in African-American smokers. Clinical Pharmacology and Therapeutics. 96: 256-65. PMID 24733007 DOI: 10.1038/clpt.2014.88  1
2014 Leventhal AM, Lee W, Bergen AW, Swan GE, Tyndale RF, Lerman C, Conti DV. Nicotine dependence as a moderator of genetic influences on smoking cessation treatment outcome. Drug and Alcohol Dependence. 138: 109-17. PMID 24667010 DOI: 10.1016/j.drugalcdep.2014.02.016  1
2014 Miller RT, Miksys S, Hoffmann E, Tyndale RF. Ethanol self-administration and nicotine treatment increase brain levels of CYP2D in African green monkeys. British Journal of Pharmacology. 171: 3077-88. PMID 24611668 DOI: 10.1111/bph.12652  1
2014 Cascorbi I, Tyndale R. Progress in pharmacogenomics: Bridging the gap from research to practice Clinical Pharmacology and Therapeutics. 95: 231-235. PMID 24548984 DOI: 10.1038/clpt.2013.235  1
2014 Caudle KE, Klein TE, Hoffman JM, Muller DJ, Whirl-Carrillo M, Gong L, McDonagh EM, Sangkuhl K, Thorn CF, Schwab M, Agundez JA, Freimuth RR, Huser V, Lee MT, Iwuchukwu OF, ... ... Tyndale RF, et al. Incorporation of pharmacogenomics into routine clinical practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline development process. Current Drug Metabolism. 15: 209-17. PMID 24479687 DOI: 10.2174/1389200215666140130124910  1
2014 Chenoweth MJ, Zhu AZ, Sanderson Cox L, Ahluwalia JS, Benowitz NL, Tyndale RF. Variation in P450 oxidoreductase (POR) A503V and flavin-containing monooxygenase (FMO)-3 E158K is associated with minor alterations in nicotine metabolism, but does not alter cigarette consumption. Pharmacogenetics and Genomics. 24: 172-6. PMID 24448396 DOI: 10.1097/FPC.0000000000000031  1
2014 Schnoll RA, George TP, Hawk L, Cinciripini P, Wileyto P, Tyndale RF. The relationship between the nicotine metabolite ratio and three self-report measures of nicotine dependence across sex and race. Psychopharmacology. 231: 2515-23. PMID 24402139 DOI: 10.1007/s00213-013-3421-1  1
2014 Piliguian M, Zhu AZ, Zhou Q, Benowitz NL, Ahluwalia JS, Sanderson Cox L, Tyndale RF. Novel CYP2A6 variants identified in African Americans are associated with slow nicotine metabolism in vitro and in vivo. Pharmacogenetics and Genomics. 24: 118-28. PMID 24305170 DOI: 10.1097/FPC.0000000000000026  1
2014 Alsharari SD, Siu EC, Tyndale RF, Damaj MI. Pharmacokinetic and pharmacodynamics studies of nicotine after oral administration in mice: effects of methoxsalen, a CYP2A5/6 inhibitor. Nicotine & Tobacco Research : Official Journal of the Society For Research On Nicotine and Tobacco. 16: 18-25. PMID 23884323 DOI: 10.1093/ntr/ntt105  1
2013 David SP, Strong DR, Leventhal AM, Lancaster MA, McGeary JE, Munafò MR, Bergen AW, Swan GE, Benowitz NL, Tyndale RF, Conti DV, Brown RA, Lerman C, Niaura R. Influence of a dopamine pathway additive genetic efficacy score on smoking cessation: results from two randomized clinical trials of bupropion. Addiction (Abingdon, England). 108: 2202-11. PMID 23941313 DOI: 10.1111/add.12325  1
2013 Zhu AZ, Zhou Q, Cox LS, Ahluwalia JS, Benowitz NL, Tyndale RF. Variation in trans-3'-hydroxycotinine glucuronidation does not alter the nicotine metabolite ratio or nicotine intake. Plos One. 8: e70938. PMID 23936477 DOI: 10.1371/journal.pone.0070938  1
2013 Dempsey DA, St Helen G, Jacob P, Tyndale RF, Benowitz NL. Genetic and pharmacokinetic determinants of response to transdermal nicotine in white, black, and Asian nonsmokers. Clinical Pharmacology and Therapeutics. 94: 687-94. PMID 23933970 DOI: 10.1038/clpt.2013.159  1
2013 Roden DM, Tyndale RF. Genomic medicine, precision medicine, personalized medicine: what's in a name? Clinical Pharmacology and Therapeutics. 94: 169-72. PMID 23872826 DOI: 10.1038/clpt.2013.101  1
2013 Ogawa S, Surapisitchat J, Virtanen C, Ogawa M, Niapour M, Sugamori KS, Wang S, Tamblyn L, Guillemette C, Hoffmann E, Zhao B, Strom S, Laposa RR, Tyndale RF, Grant DM, et al. Three-dimensional culture and cAMP signaling promote the maturation of human pluripotent stem cell-derived hepatocytes. Development (Cambridge, England). 140: 3285-96. PMID 23861064 DOI: 10.1242/dev.090266  1
2013 Falcone M, Smith RM, Chenoweth MJ, Bhattacharjee AK, Kelsoe JR, Tyndale RF, Lerman C. Neuroimaging in psychiatric pharmacogenetics research: the promise and pitfalls. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 38: 2327-37. PMID 23793356 DOI: 10.1038/npp.2013.152  1
2013 Nollen NL, Mayo MS, Ahluwalia JS, Tyndale RF, Benowitz NL, Faseru B, Buchanan TS, Cox LS. Factors associated with discontinuation of bupropion and counseling among African American light smokers in a randomized clinical trial. Annals of Behavioral Medicine : a Publication of the Society of Behavioral Medicine. 46: 336-48. PMID 23733379 DOI: 10.1007/s12160-013-9510-x  1
2013 Dempsey DA, Sambol NC, Jacob P, Hoffmann E, Tyndale RF, Fuentes-Afflick E, Benowitz NL. CYP2A6 genotype but not age determines cotinine half-life in infants and children. Clinical Pharmacology and Therapeutics. 94: 400-6. PMID 23714690 DOI: 10.1038/clpt.2013.114  1
2013 Zhu AZ, Renner CC, Hatsukami DK, Benowitz NL, Tyndale RF. CHRNA5-A3-B4 genetic variants alter nicotine intake and interact with tobacco use to influence body weight in Alaska Native tobacco users. Addiction (Abingdon, England). 108: 1818-28. PMID 23692359 DOI: 10.1111/add.12250  1
2013 Ferguson CS, Miksys S, Palmour RM, Tyndale RF. Ethanol self-administration and nicotine treatment induce brain levels of CYP2B6 and CYP2E1 in African green monkeys. Neuropharmacology. 72: 74-81. PMID 23639433 DOI: 10.1016/j.neuropharm.2013.04.022  1
2013 Zhou K, Khokhar JY, Zhao B, Tyndale RF. First demonstration that brain CYP2D-mediated opiate metabolic activation alters analgesia in vivo. Biochemical Pharmacology. 85: 1848-55. PMID 23623752 DOI: 10.1016/j.bcp.2013.04.014  1
2013 Cheng J, Zhen Y, Miksys S, BeyoÄŸlu D, Krausz KW, Tyndale RF, Yu A, Idle JR, Gonzalez FJ. Potential role of CYP2D6 in the central nervous system. Xenobiotica; the Fate of Foreign Compounds in Biological Systems. 43: 973-84. PMID 23614566 DOI: 10.3109/00498254.2013.791410  1
2013 Wassenaar CA, Dong Q, Amos CI, Spitz MR, Tyndale RF. Pilot Study of CYP2B6 Genetic Variation to Explore the Contribution of Nitrosamine Activation to Lung Carcinogenesis. International Journal of Molecular Sciences. 14: 8381-92. PMID 23591849 DOI: 10.3390/ijms14048381  1
2013 Bough KJ, Lerman C, Rose JE, McClernon FJ, Kenny PJ, Tyndale RF, David SP, Stein EA, Uhl GR, Conti DV, Green C, Amur S. Biomarkers for smoking cessation. Clinical Pharmacology and Therapeutics. 93: 526-38. PMID 23588313 DOI: 10.1038/clpt.2013.57  1
2013 Miksys S, Cappendijk SL, Perry WM, Zhao B, Tyndale RF. Nicotine kinetics in zebra finches in vivo and in vitro. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 41: 1240-6. PMID 23530019 DOI: 10.1124/dmd.112.050765  1
2013 Chenoweth MJ, O'Loughlin J, Sylvestre MP, Tyndale RF. CYP2A6 slow nicotine metabolism is associated with increased quitting by adolescent smokers. Pharmacogenetics and Genomics. 23: 232-5. PMID 23462429 DOI: 10.1097/FPC.0b013e32835f834d  1
2013 Esterlis I, Hannestad JO, Perkins E, Bois F, D'Souza DC, Tyndale RF, Seibyl JP, Hatsukami DM, Cosgrove KP, O'Malley SS. Effect of a nicotine vaccine on nicotine binding to β2*-nicotinic acetylcholine receptors in vivo in human tobacco smokers. The American Journal of Psychiatry. 170: 399-407. PMID 23429725 DOI: 10.1176/appi.ajp.2012.12060793  1
2013 Zhu AZ, Renner CC, Hatsukami DK, Swan GE, Lerman C, Benowitz NL, Tyndale RF. The ability of plasma cotinine to predict nicotine and carcinogen exposure is altered by differences in CYP2A6: the influence of genetics, race, and sex. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 22: 708-18. PMID 23371292 DOI: 10.1158/1055-9965.EPI-12-1234-T  1
2013 Sellings L, Pereira S, Qian C, Dixon-McDougall T, Nowak C, Zhao B, Tyndale RF, van der Kooy D. Nicotine-motivated behavior in Caenorhabditis elegans requires the nicotinic acetylcholine receptor subunits acr-5 and acr-15. The European Journal of Neuroscience. 37: 743-56. PMID 23351035 DOI: 10.1111/ejn.12099  1
2013 Benowitz NL, Zhu AZ, Tyndale RF, Dempsey D, Jacob P. Influence of CYP2B6 genetic variants on plasma and urine concentrations of bupropion and metabolites at steady state. Pharmacogenetics and Genomics. 23: 135-41. PMID 23344581 DOI: 10.1097/FPC.0b013e32835d9ab0  1
2013 Ting-A-Kee R, Vargas-Perez H, Bufalino MR, Bahi A, Dreyer JL, Tyndale RF, van der Kooy D. Infusion of brain-derived neurotrophic factor into the ventral tegmental area switches the substrates mediating ethanol motivation. The European Journal of Neuroscience. 37: 996-1003. PMID 23279128 DOI: 10.1111/ejn.12105  1
2013 Faseru B, Nollen NL, Mayo MS, Krebill R, Choi WS, Benowitz NL, Tyndale RF, Okuyemi KS, Ahluwalia JS, Sanderson Cox L. Predictors of cessation in African American light smokers enrolled in a bupropion clinical trial. Addictive Behaviors. 38: 1796-803. PMID 23254230 DOI: 10.1016/j.addbeh.2012.11.010  1
2013 Bergen AW, Javitz HS, Krasnow R, Nishita D, Michel M, Conti DV, Liu J, Lee W, Edlund CK, Hall S, Kwok PY, Benowitz NL, Baker TB, Tyndale RF, Lerman C, et al. Nicotinic acetylcholine receptor variation and response to smoking cessation therapies. Pharmacogenetics and Genomics. 23: 94-103. PMID 23249876 DOI: 10.1097/FPC.0b013e32835cdabd  1
2013 Bergen AW, Javitz HS, Su L, He Y, Conti DV, Benowitz NL, Tyndale RF, Lerman C, Swan GE. The DRD4 exon III VNTR, bupropion, and associations with prospective abstinence. Nicotine & Tobacco Research : Official Journal of the Society For Research On Nicotine and Tobacco. 15: 1190-200. PMID 23212438 DOI: 10.1093/ntr/nts245  1
2013 Miksys S, Tyndale RF. Cytochrome P450-mediated drug metabolism in the brain. Journal of Psychiatry & Neuroscience : Jpn. 38: 152-63. PMID 23199531 DOI: 10.1503/jpn.120133  1
2013 Esterlis I, Hannestad JO, Bois F, Sewell RA, Tyndale RF, Seibyl JP, Picciotto MR, Laruelle M, Carson RE, Cosgrove KP. Imaging changes in synaptic acetylcholine availability in living human subjects. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine. 54: 78-82. PMID 23160789 DOI: 10.2967/jnumed.112.111922  1
2013 Zhu AZ, Binnington MJ, Renner CC, Lanier AP, Hatsukami DK, Stepanov I, Watson CH, Sosnoff CS, Benowitz NL, Tyndale RF. Alaska Native smokers and smokeless tobacco users with slower CYP2A6 activity have lower tobacco consumption, lower tobacco-specific nitrosamine exposure and lower tobacco-specific nitrosamine bioactivation. Carcinogenesis. 34: 93-101. PMID 23027621 DOI: 10.1093/carcin/bgs306  1
2013 Renner CC, Lanier AP, Lindgren B, Jensen J, Patten CA, Parascandola M, Benowitz NL, Tyndale RF, Hatsukami DK. Tobacco use among southwestern Alaska Native people. Nicotine & Tobacco Research : Official Journal of the Society For Research On Nicotine and Tobacco. 15: 401-6. PMID 22949573 DOI: 10.1093/ntr/nts137  1
2013 Schnoll RA, Wileyto EP, Leone FT, Tyndale RF, Benowitz NL. High dose transdermal nicotine for fast metabolizers of nicotine: a proof of concept placebo-controlled trial. Nicotine & Tobacco Research : Official Journal of the Society For Research On Nicotine and Tobacco. 15: 348-54. PMID 22589423 DOI: 10.1093/ntr/nts129  1
2013 Benowitz NL, Dempsey D, Tyndale RF, St Helen G, Jacob P. Dose-independent kinetics with low level exposure to nicotine and cotinine. British Journal of Clinical Pharmacology. 75: 277-9. PMID 22574797 DOI: 10.1111/j.1365-2125.2012.04327.x  1
2013 Liu T, Tyndale RF, David SP, Wang H, Yu XQ, Chen W, Wen XZ, Chen WQ. Association between daily cigarette consumption and hypertension moderated by CYP2A6 genotypes in Chinese male current smokers. Journal of Human Hypertension. 27: 24-30. PMID 22217675 DOI: 10.1038/jhh.2011.111  1
2012 Zhu AZ, Cox LS, Nollen N, Faseru B, Okuyemi KS, Ahluwalia JS, Benowitz NL, Tyndale RF. CYP2B6 and bupropion's smoking-cessation pharmacology: the role of hydroxybupropion. Clinical Pharmacology and Therapeutics. 92: 771-7. PMID 23149928 DOI: 10.1038/clpt.2012.186  1
2012 Ferguson CS, Miksys S, Palmour RM, Tyndale RF. Differential effects of nicotine treatment and ethanol self-administration on CYP2A6, CYP2B6 and nicotine pharmacokinetics in African green monkeys. The Journal of Pharmacology and Experimental Therapeutics. 343: 628-37. PMID 22935730 DOI: 10.1124/jpet.112.198564  1
2012 Mahar I, Bagot RC, Davoli MA, Miksys S, Tyndale RF, Walker CD, Maheu M, Huang SH, Wong TP, Mechawar N. Developmental hippocampal neuroplasticity in a model of nicotine replacement therapy during pregnancy and breastfeeding. Plos One. 7: e37219. PMID 22615944 DOI: 10.1371/journal.pone.0037219  1
2012 Binnington MJ, Zhu AZ, Renner CC, Lanier AP, Hatsukami DK, Benowitz NL, Tyndale RF. CYP2A6 and CYP2B6 genetic variation and its association with nicotine metabolism in South Western Alaska Native people. Pharmacogenetics and Genomics. 22: 429-40. PMID 22569203 DOI: 10.1097/FPC.0b013e3283527c1c  1
2012 St Helen G, Novalen M, Heitjan DF, Dempsey D, Jacob P, Aziziyeh A, Wing VC, George TP, Tyndale RF, Benowitz NL. Reproducibility of the nicotine metabolite ratio in cigarette smokers. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 21: 1105-14. PMID 22552800 DOI: 10.1158/1055-9965.EPI-12-0236  1
2012 McDonagh EM, Wassenaar C, David SP, Tyndale RF, Altman RB, Whirl-Carrillo M, Klein TE. PharmGKB summary: very important pharmacogene information for cytochrome P-450, family 2, subfamily A, polypeptide 6. Pharmacogenetics and Genomics. 22: 695-708. PMID 22547082 DOI: 10.1097/FPC.0b013e3283540217  1
2012 Lee W, Ray R, Bergen AW, Swan GE, Thomas P, Tyndale RF, Benowitz NL, Lerman C, Conti DV. DRD1 associations with smoking abstinence across slow and normal nicotine metabolizers. Pharmacogenetics and Genomics. 22: 551-4. PMID 22495174 DOI: 10.1097/FPC.0b013e3283539062  1
2012 Benowitz NL, Renner CC, Lanier AP, Tyndale RF, Hatsukami DK, Lindgren B, Stepanov I, Watson CH, Sosnoff CS, Jacob P. Exposure to nicotine and carcinogens among Southwestern Alaskan Native cigarette smokers and smokeless tobacco users. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 21: 934-42. PMID 22490317 DOI: 10.1158/1055-9965.EPI-11-1178  1
2012 Tang DW, Hello B, Mroziewicz M, Fellows LK, Tyndale RF, Dagher A. Genetic variation in CYP2A6 predicts neural reactivity to smoking cues as measured using fMRI. Neuroimage. 60: 2136-43. PMID 22342802 DOI: 10.1016/j.neuroimage.2012.01.119  1
2012 Khokhar JY, Tyndale RF. Rat brain CYP2B-enzymatic activation of chlorpyrifos to the oxon mediates cholinergic neurotoxicity. Toxicological Sciences : An Official Journal of the Society of Toxicology. 126: 325-35. PMID 22287024 DOI: 10.1093/toxsci/kfs029  1
2012 Cox LS, Nollen NL, Mayo MS, Choi WS, Faseru B, Benowitz NL, Tyndale RF, Okuyemi KS, Ahluwalia JS. Bupropion for smoking cessation in African American light smokers: a randomized controlled trial. Journal of the National Cancer Institute. 104: 290-8. PMID 22282543 DOI: 10.1093/jnci/djr513  1
2012 Kohli U, Pandharipande P, Muszkat M, Sofowora GG, Friedman EA, Scheinin M, Wood AJ, Ely EW, Tyndale RF, Choi L, Stein CM, Kurnik D. CYP2A6 genetic variation and dexmedetomidine disposition. European Journal of Clinical Pharmacology. 68: 937-42. PMID 22271297 DOI: 10.1007/s00228-011-1208-z  1
2012 Miksys SL, Uhl K, Tyndale RF. Twenty-first-century neuroscience: the potential for innovative therapies for brain disorders. Clinical Pharmacology and Therapeutics. 91: 153-7. PMID 22261679 DOI: 10.1038/clpt.2011.310  1
2012 Liu T, David SP, Tyndale RF, Wang H, Yu XQ, Chen W, Zhou Q, Chen WQ. Relationship between amounts of daily cigarette consumption and abdominal obesity moderated by CYP2A6 genotypes in Chinese male current smokers. Annals of Behavioral Medicine : a Publication of the Society of Behavioral Medicine. 43: 253-61. PMID 22160797 DOI: 10.1007/s12160-011-9318-5  1
2012 Mann A, Miksys SL, Gaedigk A, Kish SJ, Mash DC, Tyndale RF. The neuroprotective enzyme CYP2D6 increases in the brain with age and is lower in Parkinson's disease patients. Neurobiology of Aging. 33: 2160-71. PMID 21958961 DOI: 10.1016/j.neurobiolaging.2011.08.014  1
2012 Lee W, Bergen AW, Swan GE, Li D, Liu J, Thomas P, Tyndale RF, Benowitz NL, Lerman C, Conti DV. Gender-stratified gene and gene-treatment interactions in smoking cessation. The Pharmacogenomics Journal. 12: 521-32. PMID 21808284 DOI: 10.1038/tpj.2011.30  1
2012 Zhu AZX, Tyndale RF. Nicotine Metabolism and its Implications Metabolism of Drugs and Other Xenobiotics. 465-492. DOI: 10.1002/9783527630905.ch17  1
2011 Desta Z, Kreutz Y, Nguyen AT, Li L, Skaar T, Kamdem LK, Henry NL, Hayes DF, Storniolo AM, Stearns V, Hoffmann E, Tyndale RF, Flockhart DA. Plasma letrozole concentrations in postmenopausal women with breast cancer are associated with CYP2A6 genetic variants, body mass index, and age. Clinical Pharmacology and Therapeutics. 90: 693-700. PMID 21975350 DOI: 10.1038/clpt.2011.174  1
2011 Ferguson CS, Tyndale RF. Cytochrome P450 enzymes in the brain: emerging evidence of biological significance. Trends in Pharmacological Sciences. 32: 708-14. PMID 21975165 DOI: 10.1016/j.tips.2011.08.005  1
2011 Liu T, Chen WQ, David SP, Tyndale RF, Wang H, Chen YM, Yu XQ, Chen W, Zhou Q, Ling WH. Interaction between heavy smoking and CYP2A6 genotypes on type 2 diabetes and its possible pathways. European Journal of Endocrinology / European Federation of Endocrine Societies. 165: 961-7. PMID 21964962 DOI: 10.1530/EJE-11-0596  1
2011 Cunningham JA, Leatherdale ST, Selby PL, Tyndale RF, Zawertailo L, Kushnir V. Randomized controlled trial of mailed Nicotine Replacement Therapy to Canadian smokers: study protocol. Bmc Public Health. 11: 741. PMID 21955930 DOI: 10.1186/1471-2458-11-741  1
2011 Ferguson CS, Miksys S, Palmour R, Tyndale RF. Independent and combined effects of ethanol self-administration and nicotine treatment on hepatic CYP2E1 in African green monkeys. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 39: 2233-41. PMID 21868470 DOI: 10.1124/dmd.111.040378  1
2011 Wassenaar CA, Dong Q, Wei Q, Amos CI, Spitz MR, Tyndale RF. Relationship between CYP2A6 and CHRNA5-CHRNA3-CHRNB4 variation and smoking behaviors and lung cancer risk. Journal of the National Cancer Institute. 103: 1342-6. PMID 21747048 DOI: 10.1093/jnci/djr237  1
2011 Falcone M, Jepson C, Benowitz N, Bergen AW, Pinto A, Wileyto EP, Baldwin D, Tyndale RF, Lerman C, Ray R. Association of the nicotine metabolite ratio and CHRNA5/CHRNA3 polymorphisms with smoking rate among treatment-seeking smokers. Nicotine & Tobacco Research : Official Journal of the Society For Research On Nicotine and Tobacco. 13: 498-503. PMID 21385908 DOI: 10.1093/ntr/ntr012  1
2011 Roden DM, Tyndale RF. Pharmacogenomics at the tipping point: challenges and opportunities. Clinical Pharmacology and Therapeutics. 89: 323-7. PMID 21326256 DOI: 10.1038/clpt.2010.340  1
2011 Cox LS, Faseru B, Mayo MS, Krebill R, Snow TS, Bronars CA, Nollen NL, Choi WS, Okuyemi KS, Salzman GA, Benowitz NL, Tyndale RF, Ahluwalia JS. Design, baseline characteristics, and retention of African American light smokers into a randomized trial involving biological data. Trials. 12: 22. PMID 21266057 DOI: 10.1186/1745-6215-12-22  1
2011 Strasser AA, Benowitz NL, Pinto AG, Tang KZ, Hecht SS, Carmella SG, Tyndale RF, Lerman CE. Nicotine metabolite ratio predicts smoking topography and carcinogen biomarker level. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 20: 234-8. PMID 21212060 DOI: 10.1158/1055-9965.EPI-10-0674  1
2011 Liu T, David SP, Tyndale RF, Wang H, Zhou Q, Ding P, He YH, Yu XQ, Chen W, Crump C, Wen XZ, Chen WQ. Associations of CYP2A6 genotype with smoking behaviors in southern China. Addiction (Abingdon, England). 106: 985-94. PMID 21205058 DOI: 10.1111/j.1360-0443.2010.03353.x  1
2011 Khokhar JY, Tyndale RF. Drug metabolism within the brain changes drug response: selective manipulation of brain CYP2B alters propofol effects. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 36: 692-700. PMID 21107310 DOI: 10.1038/npp.2010.202  1
2011 Rehm J, Giesbrecht N, Gliksman L, Graham K, Le AD, Mann RE, Room R, Rush B, Tyndale RF, Wells S. Addiction Research Centres and the Nurturing of Creativity. Substance abuse research in a modern health care centre: the case of the Centre for Addiction and Mental Health. Addiction (Abingdon, England). 106: 689-97. PMID 20491727 DOI: 10.1111/j.1360-0443.2010.02955.x  1
2010 Mroziewicz M, Tyndale RF. Pharmacogenetics: a tool for identifying genetic factors in drug dependence and response to treatment. Addiction Science & Clinical Practice. 5: 17-29. PMID 22002450  1
2010 Ho MK, Goldman D, Heinz A, Kaprio J, Kreek MJ, Li MD, Munafò MR, Tyndale RF. Breaking barriers in the genomics and pharmacogenetics of drug addiction. Clinical Pharmacology and Therapeutics. 88: 779-91. PMID 20981002 DOI: 10.1038/clpt.2010.175  1
2010 Miksys SL, Tyndale RF. Neurodegenerative diseases: a growing challenge. Clinical Pharmacology and Therapeutics. 88: 427-30. PMID 20856233 DOI: 10.1038/clpt.2010.198  1
2010 Khokhar JY, Miksys SL, Tyndale RF. Rat brain CYP2B induction by nicotine is persistent and does not involve nicotinic acetylcholine receptors. Brain Research. 1348: 1-9. PMID 20599831 DOI: 10.1016/j.brainres.2010.06.035  1
2010 Mann A, Tyndale RF. Cytochrome P450 2D6 enzyme neuroprotects against 1-methyl-4-phenylpyridinium toxicity in SH-SY5Y neuronal cells. The European Journal of Neuroscience. 31: 1185-93. PMID 20345925 DOI: 10.1111/j.1460-9568.2010.07142.x  1
2010 Lerman C, Jepson C, Wileyto EP, Patterson F, Schnoll R, Mroziewicz M, Benowitz N, Tyndale RF. Genetic variation in nicotine metabolism predicts the efficacy of extended-duration transdermal nicotine therapy. Clinical Pharmacology and Therapeutics. 87: 553-7. PMID 20336063 DOI: 10.1038/clpt.2010.3  1
2010 Al Koudsi N, Tyndale RF. Hepatic CYP2B6 is altered by genetic, physiologic, and environmental factors but plays little role in nicotine metabolism. Xenobiotica; the Fate of Foreign Compounds in Biological Systems. 40: 381-92. PMID 20307138 DOI: 10.3109/00498251003713958  1
2010 Mwenifumbo JC, Zhou Q, Benowitz NL, Sellers EM, Tyndale RF. New CYP2A6 gene deletion and conversion variants in a population of Black African descent. Pharmacogenomics. 11: 189-98. PMID 20136358 DOI: 10.2217/pgs.09.144  1
2010 Khokhar JY, Ferguson CS, Zhu AZ, Tyndale RF. Pharmacogenetics of drug dependence: role of gene variations in susceptibility and treatment. Annual Review of Pharmacology and Toxicology. 50: 39-61. PMID 20055697 DOI: 10.1146/annurev.pharmtox.010909.105826  1
2010 Zawertailo LA, Tyndale RF, Busto U, Sellers EM. Effect of metabolic blockade on the psychoactive effects of dextromethorphan. Human Psychopharmacology. 25: 71-9. PMID 20041473 DOI: 10.1002/hup.1086  1
2010 Grieder TE, Sellings LH, Vargas-Perez H, Ting-A-Kee R, Siu EC, Tyndale RF, van der Kooy D. Dopaminergic signaling mediates the motivational response underlying the opponent process to chronic but not acute nicotine. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 35: 943-54. PMID 20032966 DOI: 10.1038/npp.2009.198  1
2010 Al Koudsi N, Hoffmann EB, Assadzadeh A, Tyndale RF. Hepatic CYP2A6 levels and nicotine metabolism: impact of genetic, physiological, environmental, and epigenetic factors. European Journal of Clinical Pharmacology. 66: 239-51. PMID 20012030 DOI: 10.1007/s00228-009-0762-0  1
2010 Koudsi NA, O'Loughlin J, Rodriguez D, Audrain-McGovern J, Tyndale RF. The genetic aspects of nicotine metabolism and their impact on adolescent nicotine dependence Journal of Pediatric Biochemistry. 1: 105-123. DOI: 10.3233/JPB-2010-0014  1
2009 Ho MK, Faseru B, Choi WS, Nollen NL, Mayo MS, Thomas JL, Okuyemi KS, Ahluwalia JS, Benowitz NL, Tyndale RF. Utility and relationships of biomarkers of smoking in African-American light smokers. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 18: 3426-34. PMID 19959692 DOI: 10.1158/1055-9965.EPI-09-0956  1
2009 Miksys SL, Tyndale RF. Brain and disease: the long path to discovery and treatment. Clinical Pharmacology and Therapeutics. 86: 343-6. PMID 19763109 DOI: 10.1038/clpt.2009.168  1
2009 Thomas PD, Mi H, Swan GE, Lerman C, Benowitz N, Tyndale RF, Bergen AW, Conti DV. A systems biology network model for genetic association studies of nicotine addiction and treatment. Pharmacogenetics and Genomics. 19: 538-51. PMID 19525886 DOI: 10.1097/FPC.0b013e32832e2ced  1
2009 Bergen AW, Conti DV, Van Den Berg D, Lee W, Liu J, Li D, Guo N, Mi H, Thomas PD, Lessov-Schlaggar CN, Krasnow R, He Y, Nishita D, Jiang R, McClure JB, ... ... Tyndale RF, et al. Dopamine genes and nicotine dependence in treatment-seeking and community smokers. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 34: 2252-64. PMID 19494806 DOI: 10.1038/npp.2009.52  1
2009 Al Koudsi N, Ahluwalia JS, Lin SK, Sellers EM, Tyndale RF. A novel CYP2A6 allele (CYP2A6*35) resulting in an amino-acid substitution (Asn438Tyr) is associated with lower CYP2A6 activity in vivo. The Pharmacogenomics Journal. 9: 274-82. PMID 19365400 DOI: 10.1038/tpj.2009.11  1
2009 Swan GE, Lessov-Schlaggar CN, Bergen AW, He Y, Tyndale RF, Benowitz NL. Genetic and environmental influences on the ratio of 3'hydroxycotinine to cotinine in plasma and urine. Pharmacogenetics and Genomics. 19: 388-98. PMID 19300303 DOI: 10.1097/FPC.0b013e32832a404f  1
2009 Yue J, Khokhar J, Miksys S, Tyndale RF. Differential induction of ethanol-metabolizing CYP2E1 and nicotine-metabolizing CYP2B1/2 in rat liver by chronic nicotine treatment and voluntary ethanol intake. European Journal of Pharmacology. 609: 88-95. PMID 19285975 DOI: 10.1016/j.ejphar.2009.03.015  1
2009 Ho MK, Mwenifumbo JC, Al Koudsi N, Okuyemi KS, Ahluwalia JS, Benowitz NL, Tyndale RF. Association of nicotine metabolite ratio and CYP2A6 genotype with smoking cessation treatment in African-American light smokers. Clinical Pharmacology and Therapeutics. 85: 635-43. PMID 19279561 DOI: 10.1038/clpt.2009.19  1
2009 Mwenifumbo JC, Tyndale RF. Molecular genetics of nicotine metabolism. Handbook of Experimental Pharmacology. 235-59. PMID 19184652 DOI: 10.1007/978-3-540-69248-5_9  1
2009 Ray R, Tyndale RF, Lerman C. Nicotine dependence pharmacogenetics: role of genetic variation in nicotine-metabolizing enzymes. Journal of Neurogenetics. 23: 252-61. PMID 19169923 DOI: 10.1080/01677060802572887  1
2009 Schnoll RA, Patterson F, Wileyto EP, Tyndale RF, Benowitz N, Lerman C. Nicotine metabolic rate predicts successful smoking cessation with transdermal nicotine: a validation study. Pharmacology, Biochemistry, and Behavior. 92: 6-11. PMID 19000709 DOI: 10.1016/j.pbb.2008.10.016  1
2009 Miksys S, Tyndale RF. Brain drug-metabolizing cytochrome P450 enzymes are active in vivo, demonstrated by mechanism-based enzyme inhibition. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 34: 634-40. PMID 18668033 DOI: 10.1038/npp.2008.110  1
2009 Mwenifumbo JC, Sellers EM, Tyndale RF. Corrigendum to "Nicotine metabolism and CYP2A6 activity in a population of black African descent: Impact of gender and light smoking" [Drug Alcohol Depend. 89/1 (2007) 24-33] (DOI:10.1016/j.drugalcdep.2006.11.012) Drug and Alcohol Dependence. 104: 185. DOI: 10.1016/j.drugalcdep.2009.04.004  1
2008 Emamghoreishi M, Bokaee HR, Keshavarz M, Ghaderi A, Tyndale RF. CYP2A6 allele frequencies in an Iranian population. Archives of Iranian Medicine. 11: 613-7. PMID 18976031 DOI: 08116/AIM.007  1
2008 Mann A, Miksys S, Lee A, Mash DC, Tyndale RF. Induction of the drug metabolizing enzyme CYP2D in monkey brain by chronic nicotine treatment. Neuropharmacology. 55: 1147-55. PMID 18687346 DOI: 10.1016/j.neuropharm.2008.07.017  1
2008 Mwenifumbo JC, Sellers EM, Tyndale RF. Socioeconomic and drug use determinants of smoking status in an urban adult population of Black African descent. Nicotine & Tobacco Research : Official Journal of the Society For Research On Nicotine and Tobacco. 10: 1319-25. PMID 18686179 DOI: 10.1080/14622200802238894  1
2008 Conti DV, Lee W, Li D, Liu J, Van Den Berg D, Thomas PD, Bergen AW, Swan GE, Tyndale RF, Benowitz NL, Lerman C. Nicotinic acetylcholine receptor beta2 subunit gene implicated in a systems-based candidate gene study of smoking cessation. Human Molecular Genetics. 17: 2834-48. PMID 18593715 DOI: 10.1093/hmg/ddn181  1
2008 Patterson F, Schnoll RA, Wileyto EP, Pinto A, Epstein LH, Shields PG, Hawk LW, Tyndale RF, Benowitz N, Lerman C. Toward personalized therapy for smoking cessation: a randomized placebo-controlled trial of bupropion. Clinical Pharmacology and Therapeutics. 84: 320-5. PMID 18388868 DOI: 10.1038/clpt.2008.57  1
2008 Shram MJ, Siu EC, Li Z, Tyndale RF, Lê AD. Interactions between age and the aversive effects of nicotine withdrawal under mecamylamine-precipitated and spontaneous conditions in male Wistar rats. Psychopharmacology. 198: 181-90. PMID 18385986 DOI: 10.1007/s00213-008-1115-x  1
2008 Mwenifumbo JC, Al Koudsi N, Ho MK, Zhou Q, Hoffmann EB, Sellers EM, Tyndale RF. Novel and established CYP2A6 alleles impair in vivo nicotine metabolism in a population of Black African descent. Human Mutation. 29: 679-88. PMID 18360915 DOI: 10.1002/humu.20698  1
2008 Ho MK, Mwenifumbo JC, Zhao B, Gillam EM, Tyndale RF. A novel CYP2A6 allele, CYP2A6*23, impairs enzyme function in vitro and in vivo and decreases smoking in a population of Black-African descent. Pharmacogenetics and Genomics. 18: 67-75. PMID 18216723 DOI: 10.1097/FPC.0b013e3282f3606e  1
2008 Yue J, Miksys S, Hoffmann E, Tyndale RF. Chronic nicotine treatment induces rat CYP2D in the brain but not in the liver: an investigation of induction and time course. Journal of Psychiatry & Neuroscience : Jpn. 33: 54-63. PMID 18197273  1
2008 Siu EC, Tyndale RF. Selegiline is a mechanism-based inactivator of CYP2A6 inhibiting nicotine metabolism in humans and mice. The Journal of Pharmacology and Experimental Therapeutics. 324: 992-9. PMID 18065502 DOI: 10.1124/jpet.107.133900  1
2008 Mwenifumbo JC, Lessov-Schlaggar CN, Zhou Q, Krasnow RE, Swan GE, Benowitz NL, Tyndale RF. Identification of novel CYP2A6*1B variants: the CYP2A6*1B allele is associated with faster in vivo nicotine metabolism. Clinical Pharmacology and Therapeutics. 83: 115-21. PMID 17522595 DOI: 10.1038/sj.clpt.6100246  1
2007 Ring HZ, Valdes AM, Nishita DM, Prasad S, Jacob P, Tyndale RF, Swan GE, Benowitz NL. Gene-gene interactions between CYP2B6 and CYP2A6 in nicotine metabolism. Pharmacogenetics and Genomics. 17: 1007-15. PMID 18004205 DOI: 10.1097/01.fpc.0000220560.59972.33  1
2007 Mwenifumbo JC, Tyndale RF. Genetic variability in CYP2A6 and the pharmacokinetics of nicotine. Pharmacogenomics. 8: 1385-402. PMID 17979512 DOI: 10.2217/14622416.8.10.1385  1
2007 Wall TL, Schoedel K, Ring HZ, Luczak SE, Katsuyoshi DM, Tyndale RF. Differences in pharmacogenetics of nicotine and alcohol metabolism: review and recommendations for future research. Nicotine & Tobacco Research : Official Journal of the Society For Research On Nicotine and Tobacco. 9: S459-74. PMID 17978975 DOI: 10.1080/14622200701587045  1
2007 Lee AM, Jepson C, Shields PG, Benowitz N, Lerman C, Tyndale RF. CYP2B6 genotype does not alter nicotine metabolism, plasma levels, or abstinence with nicotine replacement therapy. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 16: 1312-4. PMID 17548706 DOI: 10.1158/1055-9965.EPI-07-0188  1
2007 Strasser AA, Malaiyandi V, Hoffmann E, Tyndale RF, Lerman C. An association of CYP2A6 genotype and smoking topography. Nicotine & Tobacco Research : Official Journal of the Society For Research On Nicotine and Tobacco. 9: 511-8. PMID 17454707 DOI: 10.1080/14622200701239605  1
2007 Giacomini KM, Brett CM, Altman RB, Benowitz NL, Dolan ME, Flockhart DA, Johnson JA, Hayes DF, Klein T, Krauss RM, Kroetz DL, McLeod HL, Nguyen AT, Ratain MJ, Relling MV, ... ... Tyndale RF, et al. The pharmacogenetics research network: from SNP discovery to clinical drug response. Clinical Pharmacology and Therapeutics. 81: 328-45. PMID 17339863 DOI: 10.1038/sj.clpt.6100087  1
2007 Tyndale RF, Payne JI, Gerber AL, Sipe JC. The fatty acid amide hydrolase C385A (P129T) missense variant in cannabis users: studies of drug use and dependence in Caucasians. American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics : the Official Publication of the International Society of Psychiatric Genetics. 144: 660-6. PMID 17290447 DOI: 10.1002/ajmg.b.30491  1
2007 Ho MK, Tyndale RF. Overview of the pharmacogenomics of cigarette smoking. The Pharmacogenomics Journal. 7: 81-98. PMID 17224913 DOI: 10.1038/sj.tpj.6500436  1
2007 Lee AM, Jepson C, Hoffmann E, Epstein L, Hawk LW, Lerman C, Tyndale RF. CYP2B6 genotype alters abstinence rates in a bupropion smoking cessation trial. Biological Psychiatry. 62: 635-41. PMID 17223085 DOI: 10.1016/j.biopsych.2006.10.005  1
2007 Siu EC, Tyndale RF. Non-nicotinic therapies for smoking cessation. Annual Review of Pharmacology and Toxicology. 47: 541-64. PMID 17209799 DOI: 10.1146/annurev.pharmtox.47.120505.105354  1
2007 Mwenifumbo JC, Sellers EM, Tyndale RF. Nicotine metabolism and CYP2A6 activity in a population of black African descent: impact of gender and light smoking. Drug and Alcohol Dependence. 89: 24-33. PMID 17161559 DOI: 10.1016/j.drugalcdep.2006.11.012  1
2007 Siu EC, Tyndale RF. Characterization and comparison of nicotine and cotinine metabolism in vitro and in vivo in DBA/2 and C57BL/6 mice. Molecular Pharmacology. 71: 826-34. PMID 17158199 DOI: 10.1124/mol.106.032086  1
2007 Audrain-McGovern J, Al Koudsi N, Rodriguez D, Wileyto EP, Shields PG, Tyndale RF. The role of CYP2A6 in the emergence of nicotine dependence in adolescents. Pediatrics. 119: e264-74. PMID 17130279 DOI: 10.1542/peds.2006-1583  1
2007 Damaj MI, Siu EC, Sellers EM, Tyndale RF, Martin BR. Inhibition of nicotine metabolism by methoxysalen: Pharmacokinetic and pharmacological studies in mice. The Journal of Pharmacology and Experimental Therapeutics. 320: 250-7. PMID 17021260 DOI: 10.1124/jpet.106.111237  1
2007 Matta SG, Balfour DJ, Benowitz NL, Boyd RT, Buccafusco JJ, Caggiula AR, Craig CR, Collins AC, Damaj MI, Donny EC, Gardiner PS, Grady SR, Heberlein U, Leonard SS, Levin ED, ... ... Tyndale RF, et al. Guidelines on nicotine dose selection for in vivo research. Psychopharmacology. 190: 269-319. PMID 16896961 DOI: 10.1007/s00213-006-0441-0  1
2006 Benowitz NL, Swan GE, Jacob P, Lessov-Schlaggar CN, Tyndale RF. CYP2A6 genotype and the metabolism and disposition kinetics of nicotine. Clinical Pharmacology and Therapeutics. 80: 457-67. PMID 17112802 DOI: 10.1016/j.clpt.2006.08.011  1
2006 Lee AM, Joshi M, Yue J, Tyndale RF. Phenobarbital induces monkey brain CYP2E1 protein but not hepatic CYP2E1, in vitro or in vivo chlorzoxazone metabolism. European Journal of Pharmacology. 552: 151-8. PMID 17049344 DOI: 10.1016/j.ejphar.2006.09.006  1
2006 Malaiyandi V, Goodz SD, Sellers EM, Tyndale RF. CYP2A6 genotype, phenotype, and the use of nicotine metabolites as biomarkers during ad libitum smoking. Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association For Cancer Research, Cosponsored by the American Society of Preventive Oncology. 15: 1812-9. PMID 17035386 DOI: 10.1158/1055-9965.EPI-05-0723  1
2006 Miksys S, Tyndale RF. Nicotine induces brain CYP enzymes: relevance to Parkinson's disease. Journal of Neural Transmission. Supplementum. 177-80. PMID 17017527  1
2006 Quik M, Parameswaran N, McCallum SE, Bordia T, Bao S, McCormack A, Kim A, Tyndale RF, Langston JW, Di Monte DA. Chronic oral nicotine treatment protects against striatal degeneration in MPTP-treated primates. Journal of Neurochemistry. 98: 1866-75. PMID 16882311 DOI: 10.1111/j.1471-4159.2006.04078.x  1
2006 Lee AM, Tyndale RF. Drugs and genotypes: how pharmacogenetic information could improve smoking cessation treatment. Journal of Psychopharmacology (Oxford, England). 20: 7-14. PMID 16785264 DOI: 10.1177/1359786806066039  1
2006 Lee AM, Yue J, Tyndale RF. In vivo and in vitro characterization of chlorzoxazone metabolism and hepatic CYP2E1 levels in African Green monkeys: induction by chronic nicotine treatment. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 34: 1508-15. PMID 16763012 DOI: 10.1124/dmd.106.010363  1
2006 Al Koudsi N, Mwenifumbo JC, Sellers EM, Benowitz NL, Swan GE, Tyndale RF. Characterization of the novel CYP2A6*21 allele using in vivo nicotine kinetics. European Journal of Clinical Pharmacology. 62: 481-4. PMID 16758265 DOI: 10.1007/s00228-006-0113-3  1
2006 Lee AM, Miksys S, Tyndale RF. Phenobarbital increases monkey in vivo nicotine disposition and induces liver and brain CYP2B6 protein. British Journal of Pharmacology. 148: 786-94. PMID 16751792 DOI: 10.1038/sj.bjp.0706787  1
2006 Karp I, O'Loughlin J, Hanley J, Tyndale RF, Paradis G. Risk factors for tobacco dependence in adolescent smokers. Tobacco Control. 15: 199-204. PMID 16728750 DOI: 10.1136/tc.2005.014118  1
2006 Siu EC, Wildenauer DB, Tyndale RF. Nicotine self-administration in mice is associated with rates of nicotine inactivation by CYP2A5. Psychopharmacology. 184: 401-8. PMID 16485141 DOI: 10.1007/s00213-006-0306-6  1
2006 Joshi M, Tyndale RF. Induction and recovery time course of rat brain CYP2E1 after nicotine treatment. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 34: 647-52. PMID 16434548 DOI: 10.1124/dmd.105.008029  1
2006 McCallum SE, Parameswaran N, Bordia T, Fan H, Tyndale RF, Langston JW, McIntosh JM, Quik M. Increases in alpha4* but not alpha3*/alpha6* nicotinic receptor sites and function in the primate striatum following chronic oral nicotine treatment. Journal of Neurochemistry. 96: 1028-41. PMID 16412091 DOI: 10.1111/j.1471-4159.2005.03646.x  1
2006 Malaiyandi V, Lerman C, Benowitz NL, Jepson C, Patterson F, Tyndale RF. Impact of CYP2A6 genotype on pretreatment smoking behaviour and nicotine levels from and usage of nicotine replacement therapy. Molecular Psychiatry. 11: 400-9. PMID 16402128 DOI: 10.1038/sj.mp.4001794  1
2006 Joshi M, Tyndale RF. Regional and cellular distribution of CYP2E1 in monkey brain and its induction by chronic nicotine. Neuropharmacology. 50: 568-75. PMID 16368115 DOI: 10.1016/j.neuropharm.2005.11.001  1
2006 Lee AM, Miksys S, Palmour R, Tyndale RF. CYP2B6 is expressed in African Green monkey brain and is induced by chronic nicotine treatment. Neuropharmacology. 50: 441-50. PMID 16309716 DOI: 10.1016/j.neuropharm.2005.10.003  1
2006 Jarvis MJ, Perkins K, Picciotto MR, Clarke PBS, Corrigall WA, Shiffman S, Balfour D, Caggiula A, Tyndale RF, Bertrand D. General discussion I Novartis Foundation Symposium. 275: 59-63.  1
2006 Tyndale RF, Shiffman S, Brody AL, Clarke PBS, Walton R, Jarvis MJ, Hajek P, West R, Perkins K, Balfour D, Stolerman I. Discussion Novartis Foundation Symposium. 275: 231-234.  1
2006 Tyndale RF, Sellers EM. Modifying the metabolism of nicotine as a therapeutic strategy Novartis Foundation Symposium. 275: 235-244.  1
2006 Markou A, Jarvis MJ, Stolerman I, Picciotto MR, Perkins K, Chiamulera C, Shiffman S, Caggiula A, Hajek P, Tyndale RF, Bertrand D, Balfour D, Bizarro L. Final discussion Novartis Foundation Symposium. 275: 262-265.  1
2006 Chiamulera C, Picciotto MR, Balfour D, Bertrand D, Clarke PBS, Corrigall WA, Caggiula A, Tyndale RF, Brody AL, Shiffman S, West R. Discussion Novartis Foundation Symposium. 275: 90-95.  1
2005 Al Koudsi N, Tyndale RF. Genetic influences on smoking: a brief review. Therapeutic Drug Monitoring. 27: 704-9. PMID 16404798 DOI: 10.1097/01.ftd.0000179842.63515.c6  1
2005 Miksys SL, Cheung C, Gonzalez FJ, Tyndale RF. Human CYP2D6 and mouse CYP2Ds: organ distribution in a humanized mouse model. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 33: 1495-502. PMID 16033950 DOI: 10.1124/dmd.105.005488  1
2005 Mwenifumbo JC, Myers MG, Wall TL, Lin SK, Sellers EM, Tyndale RF. Ethnic variation in CYP2A6*7, CYP2A6*8 and CYP2A6*10 as assessed with a novel haplotyping method. Pharmacogenetics and Genomics. 15: 189-92. PMID 15861044  1
2005 Swan GE, Benowitz NL, Lessov CN, Jacob P, Tyndale RF, Wilhelmsen K. Nicotine metabolism: the impact of CYP2A6 on estimates of additive genetic influence. Pharmacogenetics and Genomics. 15: 115-25. PMID 15861035  1
2005 Malaiyandi V, Sellers EM, Tyndale RF. Implications of CYP2A6 genetic variation for smoking behaviors and nicotine dependence. Clinical Pharmacology and Therapeutics. 77: 145-58. PMID 15735609 DOI: 10.1016/j.clpt.2004.10.011  1
2005 Grabus SD, Martin BR, Batman AM, Tyndale RF, Sellers E, Damaj MI. Nicotine physical dependence and tolerance in the mouse following chronic oral administration. Psychopharmacology. 178: 183-92. PMID 15365686 DOI: 10.1007/s00213-004-2007-3  1
2004 O'Loughlin J, Paradis G, Kim W, DiFranza J, Meshefedjian G, McMillan-Davey E, Wong S, Hanley J, Tyndale RF. Genetically decreased CYP2A6 and the risk of tobacco dependence: a prospective study of novice smokers. Tobacco Control. 13: 422-8. PMID 15564629 DOI: 10.1136/tc.2003.007070  1
2004 Swan GE, Benowitz NL, Jacob P, Lessov CN, Tyndale RF, Wilhelmsen K, Krasnow RE, McElroy MR, Moore SE, Wambach M. Pharmacogenetics of nicotine metabolism in twins: methods and procedures. Twin Research : the Official Journal of the International Society For Twin Studies. 7: 435-48. PMID 15527659 DOI: 10.1375/1369052042335269  1
2004 Schoedel KA, Hoffmann EB, Rao Y, Sellers EM, Tyndale RF. Ethnic variation in CYP2A6 and association of genetically slow nicotine metabolism and smoking in adult Caucasians. Pharmacogenetics. 14: 615-26. PMID 15475735 DOI: 10.1097/00008571-200409000-00006  1
2004 McKeown-Eyssen G, Baines C, Cole DE, Riley N, Tyndale RF, Marshall L, Jazmaji V. Case-control study of genotypes in multiple chemical sensitivity: CYP2D6, NAT1, NAT2, PON1, PON2 and MTHFR. International Journal of Epidemiology. 33: 971-8. PMID 15256524 DOI: 10.1093/ije/dyh251  1
2004 Miksys S, Tyndale RF. The unique regulation of brain cytochrome P450 2 (CYP2) family enzymes by drugs and genetics. Drug Metabolism Reviews. 36: 313-33. PMID 15237857 DOI: 10.1081/DMR-120034149  1
2004 Dempsey D, Tutka P, Jacob P, Allen F, Schoedel K, Tyndale RF, Benowitz NL. Nicotine metabolite ratio as an index of cytochrome P450 2A6 metabolic activity. Clinical Pharmacology and Therapeutics. 76: 64-72. PMID 15229465 DOI: 10.1016/j.clpt.2004.02.011  1
2004 De Luca V, Wong AH, Muller DJ, Wong GW, Tyndale RF, Kennedy JL. Evidence of association between smoking and alpha7 nicotinic receptor subunit gene in schizophrenia patients. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 29: 1522-6. PMID 15100704 DOI: 10.1038/sj.npp.1300466  1
2003 Sellers EM, Ramamoorthy Y, Zeman MV, Djordjevic MV, Tyndale RF. The effect of methoxsalen on nicotine and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) metabolism in vivo. Nicotine & Tobacco Research : Official Journal of the Society For Research On Nicotine and Tobacco. 5: 891-9. PMID 14668073 DOI: 10.1080/14622200310001615231  1
2003 O'Loughlin J, DiFranza J, Tyndale RF, Meshefedjian G, McMillan-Davey E, Clarke PB, Hanley J, Paradis G. Nicotine-dependence symptoms are associated with smoking frequency in adolescents. American Journal of Preventive Medicine. 25: 219-25. PMID 14507528 DOI: 10.1016/S0749-3797(03)00198-3  1
2003 Sellers EM, Tyndale RF, Fernandes LC. Decreasing smoking behaviour and risk through CYP2A6 inhibition. Drug Discovery Today. 8: 487-93. PMID 12818518 DOI: 10.1016/S1359-6446(03)02704-1  1
2003 Miksys S, Lerman C, Shields PG, Mash DC, Tyndale RF. Smoking, alcoholism and genetic polymorphisms alter CYP2B6 levels in human brain. Neuropharmacology. 45: 122-32. PMID 12814665 DOI: 10.1016/S0028-3908(03)00136-9  1
2003 Tyndale RF. Genetics of alcohol and tobacco use in humans. Annals of Medicine. 35: 94-121. PMID 12795339 DOI: 10.1080/07853890310010014  1
2003 Howard LA, Ahluwalia JS, Lin SK, Sellers EM, Tyndale RF. CYP2E1*1D regulatory polymorphism: association with alcohol and nicotine dependence. Pharmacogenetics. 13: 321-8. PMID 12777962 DOI: 10.1097/01.fpc.0000054090.48725.a2  1
2003 Zhang W, Ramamoorthy Y, Tyndale RF, Sellers EM. Interaction of buprenorphine and its metabolite norbuprenorphine with cytochromes p450 in vitro. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 31: 768-72. PMID 12756210  1
2003 Micu AL, Miksys S, Sellers EM, Koop DR, Tyndale RF. Rat hepatic CYP2E1 is induced by very low nicotine doses: an investigation of induction, time course, dose response, and mechanism. The Journal of Pharmacology and Experimental Therapeutics. 306: 941-7. PMID 12750430 DOI: 10.1124/jpet.103.052183  1
2003 Howard LA, Miksys S, Hoffmann E, Mash D, Tyndale RF. Brain CYP2E1 is induced by nicotine and ethanol in rat and is higher in smokers and alcoholics. British Journal of Pharmacology. 138: 1376-86. PMID 12711639 DOI: 10.1038/sj.bjp.0705146  1
2003 Gafni I, Busto UE, Tyndale RF, Kaplan HL, Sellers EM. The role of cytochrome P450 2C19 activity in flunitrazepam metabolism in vivo. Journal of Clinical Psychopharmacology. 23: 169-75. PMID 12640218 DOI: 10.1097/00004714-200304000-00009  1
2003 Schoedel KA, Tyndale RF. Induction of nicotine-metabolizing CYP2B1 by ethanol and ethanol-metabolizing CYP2E1 by nicotine: summary and implications. Biochimica Et Biophysica Acta. 1619: 283-90. PMID 12573488 DOI: 10.1016/S0304-4165(02)00487-7  1
2003 Schoedel KA, Sellers EM, Palmour R, Tyndale RF. Down-regulation of hepatic nicotine metabolism and a CYP2A6-like enzyme in African green monkeys after long-term nicotine administration. Molecular Pharmacology. 63: 96-104. PMID 12488541 DOI: 10.1124/mol.63.1.96  1
2002 Ahijevych KL, Tyndale RF, Dhatt RK, Weed HG, Browning KK. Factors influencing cotinine half-life during smoking abstinence in African American and Caucasian women. Nicotine & Tobacco Research : Official Journal of the Society For Research On Nicotine and Tobacco. 4: 423-31. PMID 12521401 DOI: 10.1080/1462220021000018452  1
2002 Miksys SL, Tyndale RF. Drug-metabolizing cytochrome P450s in the brain. Journal of Psychiatry & Neuroscience : Jpn. 27: 406-15. PMID 12491573  0.72
2002 Goodz SD, Tyndale RF. Genotyping human CYP2A6 variants. Methods in Enzymology. 357: 59-69. PMID 12424898  0.12
2002 Xu C, Goodz S, Sellers EM, Tyndale RF. CYP2A6 genetic variation and potential consequences. Advanced Drug Delivery Reviews. 54: 1245-56. PMID 12406643  0.48
2002 Miksys S, Rao Y, Hoffmann E, Mash DC, Tyndale RF. Regional and cellular expression of CYP2D6 in human brain: higher levels in alcoholics. Journal of Neurochemistry. 82: 1376-87. PMID 12354285 DOI: 10.1046/j.1471-4159.2002.01069.x  1
2002 Ramamoorthy Y, Yu AM, Suh N, Haining RL, Tyndale RF, Sellers EM. Reduced (+/-)-3,4-methylenedioxymethamphetamine ("Ecstasy") metabolism with cytochrome P450 2D6 inhibitors and pharmacogenetic variants in vitro. Biochemical Pharmacology. 63: 2111-9. PMID 12110370  0.48
2002 Zhang W, Ramamoorthy Y, Tyndale RF, Glick SD, Maisonneuve IM, Kuehne ME, Sellers EM. Metabolism of 18-methoxycoronaridine, an ibogaine analog, to 18-hydroxycoronaridine by genetically variable CYP2C19. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 30: 663-9. PMID 12019193 DOI: 10.1124/dmd.30.6.663  1
2002 Pritzker D, Kanungo A, Kilicarslan T, Tyndale RF, Sellers EM. Designer drugs that are potent inhibitors of CYP2D6. Journal of Clinical Psychopharmacology. 22: 330-2. PMID 12006905  0.48
2002 Fernandes LC, Kilicarslan T, Kaplan HL, Tyndale RF, Sellers EM, Romach MK. Treatment of codeine dependence with inhibitors of cytochrome P450 2D6. Journal of Clinical Psychopharmacology. 22: 326-9. PMID 12006904  0.48
2002 Howard LA, Sellers EM, Tyndale RF. The role of pharmacogenetically-variable cytochrome P450 enzymes in drug abuse and dependence. Pharmacogenomics. 3: 185-99. PMID 11972441 DOI: 10.1517/14622416.3.2.185  1
2002 Zhang W, Ramamoorthy Y, Kilicarslan T, Nolte H, Tyndale RF, Sellers EM. Inhibition of cytochromes P450 by antifungal imidazole derivatives. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 30: 314-8. PMID 11854151  0.48
2002 Tyndale RF, Sellers EM. Genetic variation in CYP2A6-mediated nicotine metabolism alters smoking behavior. Therapeutic Drug Monitoring. 24: 163-71. PMID 11805739  0.48
2002 Xu C, Rao YS, Xu B, Hoffmann E, Jones J, Sellers EM, Tyndale RF. An in vivo pilot study characterizing the new CYP2A6*7, *8, and *10 alleles. Biochemical and Biophysical Research Communications. 290: 318-24. PMID 11779172 DOI: 10.1006/bbrc.2001.6209  1
2001 Gaedigk A, Casley WL, Tyndale RF, Sellers EM, Jurima-Romet M, Leeder JS. Cytochrome P4502C9 (CYP2C9) allele frequencies in Canadian Native Indian and Inuit populations. Canadian Journal of Physiology and Pharmacology. 79: 841-7. PMID 11697742  0.48
2001 Howard LA, Micu AL, Sellers EM, Tyndale RF. Low doses of nicotine and ethanol induce CYP2E1 and chlorzoxazone metabolism in rat liver. The Journal of Pharmacology and Experimental Therapeutics. 299: 542-50. PMID 11602665  1
2001 Schoedel KA, Sellers EM, Tyndale RF. Induction of CYP2B1/2 and nicotine metabolism by ethanol in rat liver but not rat brain. Biochemical Pharmacology. 62: 1025-36. PMID 11597571 DOI: 10.1016/S0006-2952(01)00744-4  1
2001 Ramamoorthy Y, Tyndale RF, Sellers EM. Cytochrome P450 2D6.1 and cytochrome P450 2D6.10 differ in catalytic activity for multiple substrates. Pharmacogenetics. 11: 477-87. PMID 11505218  0.48
2001 Petrie J, Sapp DW, Tyndale RF, Park MK, Fanselow M, Olsen RW. Altered gabaa receptor subunit and splice variant expression in rats treated with chronic intermittent ethanol. Alcoholism, Clinical and Experimental Research. 25: 819-28. PMID 11410716  1
2001 Zhang W, Kilicarslan T, Tyndale RF, Sellers EM. Evaluation of methoxsalen, tranylcypromine, and tryptamine as specific and selective CYP2A6 inhibitors in vitro. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 29: 897-902. PMID 11353760  0.48
2001 Tyndale RF, Sellers EM. Variable CYP2A6-mediated nicotine metabolism alters smoking behavior and risk. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 29: 548-52. PMID 11259349  0.48
2001 Kilicarslan T, Haining RL, Rettie AE, Busto U, Tyndale RF, Sellers EM. Flunitrazepam metabolism by cytochrome P450S 2C19 and 3A4. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 29: 460-5. PMID 11259331  1
2001 Wong JM, Harper PA, Meyer UA, Bock KW, Morike K, Lagueux J, Ayotte P, Tyndale RF, Sellers EM, Manchester DK, Okey AB. Ethnic variability in the allelic distribution of human aryl hydrocarbon receptor codon 554 and assessment of variant receptor function in vitro. Pharmacogenetics. 11: 85-94. PMID 11207035 DOI: 10.1097/00008571-200102000-00010  1
2000 Mash DC, Kovera CA, Pablo J, Tyndale RF, Ervin FD, Williams IC, Singleton EG, Mayor M. Ibogaine: complex pharmacokinetics, concerns for safety, and preliminary efficacy measures. Annals of the New York Academy of Sciences. 914: 394-401. PMID 11085338  1
2000 Rao Y, Hoffmann E, Zia M, Bodin L, Zeman M, Sellers EM, Tyndale RF. Duplications and defects in the CYP2A6 gene: identification, genotyping, and in vivo effects on smoking. Molecular Pharmacology. 58: 747-55. PMID 10999944  0.48
2000 Sellers EM, Kaplan HL, Tyndale RF. Inhibition of cytochrome P450 2A6 increases nicotine's oral bioavailability and decreases smoking. Clinical Pharmacology and Therapeutics. 68: 35-43. PMID 10945314 DOI: 10.1067/mcp.2000.107651  0.48
2000 Miksys S, Rao Y, Sellers EM, Kwan M, Mendis D, Tyndale RF. Regional and cellular distribution of CYP2D subfamily members in rat brain. Xenobiotica; the Fate of Foreign Compounds in Biological Systems. 30: 547-64. PMID 10923858 DOI: 10.1080/004982500406390  1
2000 Kathiramalainathan K, Kaplan HL, Romach MK, Busto UE, Li NY, Säwe J, Tyndale RF, Sellers EM. Inhibition of cytochrome P450 2D6 modifies codeine abuse liability. Journal of Clinical Psychopharmacology. 20: 435-44. PMID 10917405 DOI: 10.1097/00004714-200008000-00008  1
2000 Sellers EM, Tyndale RF. Mimicking gene defects to treat drug dependence. Annals of the New York Academy of Sciences. 909: 233-46. PMID 10911933  0.48
2000 Vandenbergh DJ, Thompson MD, Cook EH, Bendahhou E, Nguyen T, Krasowski MD, Zarrabian D, Comings D, Sellers EM, Tyndale RF, George SR, O'Dowd BF, Uhl GR. Human dopamine transporter gene: coding region conservation among normal, Tourette's disorder, alcohol dependence and attention-deficit hyperactivity disorder populations. Molecular Psychiatry. 5: 283-92. PMID 10889531  1
2000 Miksys S, Hoffmann E, Tyndale RF. Regional and cellular induction of nicotine-metabolizing CYP2B1 in rat brain by chronic nicotine treatment. Biochemical Pharmacology. 59: 1501-11. PMID 10799646  0.52
2000 Davies PA, Hoffmann EB, Carlisle HJ, Tyndale RF, Hales TG. The influence of an endogenous beta3 subunit on recombinant GABA(A) receptor assembly and pharmacology in WSS-1 cells and transiently transfected HEK293 cells. Neuropharmacology. 39: 611-20. PMID 10728882 DOI: 10.1016/S0028-3908(99)00163-X  1
2000 Romach MK, Otton SV, Somer G, Tyndale RF, Sellers EM. Cytochrome P450 2D6 and treatment of codeine dependence. Journal of Clinical Psychopharmacology. 20: 43-5. PMID 10653207  0.48
1999 Tyndale RF, Pianezza ML, Sellers EM. A common genetic defect in nicotine metabolism decreases risk for dependence and lowers cigarette consumption. Nicotine & Tobacco Research : Official Journal of the Society For Research On Nicotine and Tobacco. 1: S63-7; discussion S6. PMID 11768189  0.48
1999 Ozdemir V, Tyndale RF, Reed K, Herrmann N, Sellers EM, Kalow W, Naranjo CA. Paroxetine steady-state plasma concentration in relation to CYP2D6 genotype in extensive metabolizers. Journal of Clinical Psychopharmacology. 19: 472-5. PMID 10505591  0.52
1999 Tyndale RF, Li Y, Li NY, Messina E, Miksys S, Sellers EM. Characterization of cytochrome P-450 2D1 activity in rat brain: high-affinity kinetics for dextromethorphan. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 27: 924-30. PMID 10421620  0.52
1998 Nowak MP, Sellers EM, Tyndale RF. Canadian Native Indians exhibit unique CYP2A6 and CYP2C19 mutant allele frequencies. Clinical Pharmacology and Therapeutics. 64: 378-83. PMID 9797794 DOI: 10.1016/S0009-9236(98)90068-6  0.48
1998 Droll K, Bruce-Mensah K, Otton SV, Gaedigk A, Sellers EM, Tyndale RF. Comparison of three CYP2D6 probe substrates and genotype in Ghanaians, Chinese and Caucasians. Pharmacogenetics. 8: 325-33. PMID 9731719  0.48
1998 Gaedigk A, Tyndale RF, Jurima-Romet M, Sellers EM, Grant DM, Leeder JS. NAD(P)H:quinone oxidoreductase: polymorphisms and allele frequencies in Caucasian, Chinese and Canadian Native Indian and Inuit populations. Pharmacogenetics. 8: 305-13. PMID 9731717  0.48
1998 Zawertailo LA, Kaplan HL, Busto UE, Tyndale RF, Sellers EM. Psychotropic effects of dextromethorphan are altered by the CYP2D6 polymorphism: a pilot study. Journal of Clinical Psychopharmacology. 18: 332-7. PMID 9690700 DOI: 10.1097/00004714-199808000-00014  1
1998 Pianezza ML, Sellers EM, Tyndale RF. Nicotine metabolism defect reduces smoking. Nature. 393: 750. PMID 9655391 DOI: 10.1038/31623  0.48
1998 Bronstein JM, Hales TG, Tyndale RF, Charles AC. A conditionally immortalized glial cell line that expresses mature myelin proteins and functional GABA(A) receptors. Journal of Neurochemistry. 70: 483-91. PMID 9453541  1
1997 Tyndale RF, Droll KP, Sellers EM. Genetically deficient CYP2D6 metabolism provides protection against oral opiate dependence. Pharmacogenetics. 7: 375-9. PMID 9352573  0.48
1997 Tyndale RF, Bhave SV, Hoffmann E, Hoffmann PL, Tabakoff B, Tobin AJ, Olsen RW. Pentobarbital decreases the gamma-aminobutyric acidA receptor subunit gamma-2 long/short mRNA ratio by a mechanism distinct from receptor occupation. The Journal of Pharmacology and Experimental Therapeutics. 283: 350-7. PMID 9336343  1
1997 Messina ES, Tyndale RF, Sellers EM. A major role for CYP2A6 in nicotine C-oxidation by human liver microsomes. The Journal of Pharmacology and Experimental Therapeutics. 282: 1608-14. PMID 9316878  0.48
1997 Sellers EM, Otton SV, Tyndale RF. The potential role of the cytochrome P-450 2D6 pharmacogenetic polymorphism in drug abuse. Nida Research Monograph. 173: 6-26. PMID 9260180  0.48
1997 Nowak MP, Tyndale RF, Sellers EM. CYP2D6 phenotype and genotype in a Canadian Native Indian population. Pharmacogenetics. 7: 145-8. PMID 9170152  0.48
1997 Cheung S, Nolte H, Otton SV, Tyndale RF, Wu PH, Sellers EM. Simultaneous gas chromatographic determination of methamphetamine, amphetamine and their p-hydroxylated metabolites in plasma and urine. Journal of Chromatography. B, Biomedical Sciences and Applications. 690: 77-87. PMID 9106031  0.48
1997 Tomkins DM, Otton SV, Joharchi N, Li NY, Balster RF, Tyndale RF, Sellers EM. Effect of cytochrome P450 2D1 inhibition on hydrocodone metabolism and its behavioral consequences in rats. The Journal of Pharmacology and Experimental Therapeutics. 280: 1374-82. PMID 9067326  0.48
1996 Grudzinskas CV, Woosley RL, Payte TJ, Collins J, Moody DE, Tyndale RF, Sellers EM. The documented role of pharmacogenetic: in the identification and administration of new medications for treating drug abuse. Nida Research Monograph. 162: 60-3. PMID 9066815  0.48
1996 Charles AC, Kodali SK, Tyndale RF. Intercellular calcium waves in neurons. Molecular and Cellular Neurosciences. 7: 337-53. PMID 8812061 DOI: 10.1006/mcne.1996.0025  1
1995 Beischlag TV, Marchese A, Meador-Woodruff JH, Damask SP, O'Dowd BF, Tyndale RF, van Tol HH, Seeman P, Niznik HB. The human dopamine D5 receptor gene: cloning and characterization of the 5'-flanking and promoter region. Biochemistry. 34: 5960-70. PMID 7727453  1
1995 Greger V, Knoll JH, Woolf E, Glatt K, Tyndale RF, DeLorey TM, Olsen RW, Tobin AJ, Sikela JM, Nakatsu Y. The gamma-aminobutyric acid receptor gamma 3 subunit gene (GABRG3) is tightly linked to the alpha 5 subunit gene (GABRA5) on human chromosome 15q11-q13 and is transcribed in the same orientation. Genomics. 26: 258-64. PMID 7601451 DOI: 10.1016/0888-7543(95)80209-5  1
1994 Hales TG, Tyndale RF. Few cell lines with GABAA mRNAs have functional receptors. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 14: 5429-36. PMID 8083746  0.52
1994 Tyndale RF, Hales TG, Olsen RW, Tobin AJ. Distinctive patterns of GABAA receptor subunit mRNAs in 13 cell lines. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 14: 5417-28. PMID 8083745  1
1993 Nakatsu Y, Tyndale RF, DeLorey TM, Durham-Pierre D, Gardner JM, McDanel HJ, Nguyen Q, Wagstaff J, Lalande M, Sikela JM. A cluster of three GABAA receptor subunit genes is deleted in a neurological mutant of the mouse p locus. Nature. 364: 448-50. PMID 8392662 DOI: 10.1038/364448a0  1
1992 Otton SV, Tyndale RF, Wu D, Inaba T, Kalow W, Sellers EM. Catalytic and immunologic similarities between monkey and human liver cytochrome P-450db1 (human cytochrome P-450 2D6). Drug Metabolism and Disposition: the Biological Fate of Chemicals. 20: 1-5. PMID 1346982  0.52
1991 Tyndale RF, Kalow W, Inaba T. Oxidation of reduced haloperidol to haloperidol: involvement of human P450IID6 (sparteine/debrisoquine monooxygenase). British Journal of Clinical Pharmacology. 31: 655-60. PMID 1867960  0.52
1991 Tyndale RF, Sunahara R, Inaba T, Kalow W, Gonzalez FJ, Niznik HB. Neuronal cytochrome P450IID1 (debrisoquine/sparteine-type): potent inhibition of activity by (-)-cocaine and nucleotide sequence identity to human hepatic P450 gene CYP2D6. Molecular Pharmacology. 40: 63-8. PMID 1857341  1
1991 Someya T, Inaba T, Tyndale RF, Tang SW, Takahashi S. Conversion of bromperidol to reduced bromperidol in human liver. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 5: 177-82. PMID 1755933  0.52
1990 Tyndale RF, Gonzalez FJ, Hardwick JP, Kalow W, Inaba T. Sparteine metabolism capacity in human liver: structural variants of human P450IID6 as assessed by immunochemistry. Pharmacology & Toxicology. 67: 14-8. PMID 2395811  0.52
1990 Niznik HB, Tyndale RF, Sallee FR, Gonzalez FJ, Hardwick JP, Inaba T, Kalow W. The dopamine transporter and cytochrome P45OIID1 (debrisoquine 4-hydroxylase) in brain: resolution and identification of two distinct [3H]GBR-12935 binding proteins. Archives of Biochemistry and Biophysics. 276: 424-32. PMID 2306106 DOI: 10.1016/0003-9861(90)90741-G  1
1990 Tyndale RF, Inaba T. Simultaneous determination of haloperidol and reduced haloperidol by gas chromatography using a megabore column with electron-capture detection: application to microsomal oxidation of reduced haloperidol. Journal of Chromatography. 529: 182-8. PMID 2211930  0.52
1989 Tyndale RF, Inaba T, Kalow W. Evidence in humans for variant allozymes of the nondeficient sparteine/debrisoquine monooxygenase (P45OIID 1) in vitro. Drug Metabolism and Disposition: the Biological Fate of Chemicals. 17: 334-40. PMID 2568917  0.52
Show low-probability matches.